Highlights From AHA 2023-New Risk Calculator, Semaglutide and CVD, and More [PMID: 37991804] Laboratory literature summary: Highlights From AHA 2023-New Risk Calculator, Semaglutide and CVD, and More
Future large-scale, well-designed clinical trials will be essential to confirm their therapeutic potential, clarify the contribution of metabolic versus immunological effects, and define their role within the treatment algorithm of PsO and PsA
A total of 48 patients were administered 250 mg or 500 mg of l-carnitine three times a day for 8 weeks (l-carnitine group), according to the attending physicians discretion, and the remaining 32 patients were not (control group) (Fig
For patients who want a deeper dive into how biomarkers fit into this picture, the institute's resource on longevity biomarkers helps connect hormone health to a broader longevity framework
Its essential to consult your healthcare provider to determine the most suitable medication and dosing plan for your specific needs
Your intestinal transit normalizes despite altered motility
